CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines

Prof Jeffrey S. Ross speaks to ecancer at ESMO 2019 in Barcelona about the challenging task of identifying carcinoma of unknown primary (CUP) according to ESMO guidelines.

He explains the background of the trial, which involves the use of DNA sequencing to guide a more personalised treatment for these patients.

Prof Ross outlines the design of the study, in which patients who met the ESMO guidelines for the diagnosis of CUP were screened with a DNA profiling test. This test would match patients to a treatment arm according to the molecular signatures of their tumour.

He states that over 30 percent of patients were matched to a treatment arm using immunotherapeutic or targeted agents, as opposed to the standard of care chemotherapy.

For the future, Prof Ross hopes that this new and innovative strategy will ultimately improve patient outcomes.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php